Kurz gefasst
Fachartikel in der Zeitschrift Future Prescriber, 2006. Verfasst von Sue Lyon.
Abstract (Originalsprache)
A quiet revolution is taking place within the NHS as laboratories grad‐ually switch from serum creatinine to estimated glomerular filtration rate (eGFR) as the prime measure of renal function. This change follows recommendations in the National Service Framework for Renal Services,1 but the move will have an impact far beyond the renal com‐munity, affecting health profess‐ionals and patients throughout primary and secondary care. Copyright © 2006 John Wiley & Sons, Ltd.
Zitieren
APA
Lyon, S. (2006). Improving CVD risk assessment with eGFR. Future Prescriber. https://doi.org/10.1002/fps.22
Vancouver
Lyon S. Improving CVD risk assessment with eGFR. Future Prescriber. 2006. doi:10.1002/fps.22
BibTeX
@article{Lyon2006,
author = {Lyon, Sue},
title = {Improving CVD risk assessment with eGFR},
journal = {Future Prescriber},
year = {2006},
doi = {10.1002/fps.22}
}
EUVIMED